Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC

Zongertinib shows high response rates in first-line HER2-mutant advanced NSCLC

Osimertinib plus chemo improves survival across high-risk subgroups in EGFR-mutated aNSCLC

Tarlatamab shows manageable safety profile with fewer toxicities than chemo in 2L SCLC

MCED blood test demonstrates high specificity, strong predictive value, and increased early cancer detection

Taletrectinib shows efficacy and tolerability in advanced ROS1+ NSCLC previously treated with entrectinib

NSCLC brain metastases: TTFields after SRS delays intracranial progression without affecting QoL

Supportive care intervention improves function and reduces fatigue in older lung cancer patients

Improving efficacy and toxicity reporting - and treatment insights from an oncologist patient

CURB phase II trial: Tumour burden predicts survival after SBRT in NSCLC oligoprogression

WCLC 2025: Latest in EGFR positive NSCLC

Lurbinectedin plus atezolizumab improves PFS and OS in ES-SCLC first-line maintenance